Adalimumab for Nail Psoriasis: Efficacy and Safety from the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

Main Article Content

Alice B Gottlieb
Boni E Elewski
Martin M Okun
Jerry Bagel
Yves Poulin
Yihua Gu
Ziqian Geng
David A Williams
Wendell C Valdecantos


adalimumab, nail disorders, psoriasis, nail psoriasis


Abstract Not Available

Disclosures: Study supported by AbbVie.

Most read articles by the same author(s)

1 2 3 4 > >>